Real-world Dosing Patterns of Rivaroxaban in the United States

Completed

Phase N/A Results N/A

Summary of Purpose

The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban. The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal function).

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 3 August 2017.

12 Feb 2016 26 Jul 2017 1 Mar 2016 1 Mar 2016 1 Aug 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

Not available

Contacts

Not available